OctoPlus announces agreement with a US biotechnology company on its controlled release technology

08-Jul-2010 - Netherlands

OctoPlus N.V. announced that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus' controlled release technology.

Under the contract, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance